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Novel APC promoter and exon 1B deletion and
allelic silencing in three mutation-negative classic
familial adenomatous polyposis families
Yiing Lin1, Shin Lin2, Melanie D Baxter3, Lawrence Lin1, Susan M Kennedy5, Zhengyan Zhang1, Paul J Goodfellow4,
William C Chapman1 and Nicholas O Davidson5*

Abstract
Background: The overwhelming majority (approximately 80%) of individuals with classic familial adenomatous
polyposis (FAP) exhibit mutations in the coding sequence of the adenomatous polyposis coli (APC) tumor
suppressor gene. Families without detectable APC mutations are unable to benefit from the use of genetic
testing for clinical management of this autosomal dominant syndrome.
Methods: We used exome sequencing and linkage analysis, coupled with second-generation sequencing of
the APC locus including non-coding regions to investigate three APC mutation-negative classical FAP families.
Results: We identified a novel ~11 kb deletion localized 44 kb upstream of the transcription start site of APC
that encompasses the APC 1B promoter and exon. This deletion was present only in affected family members
of one kindred with classical FAP. Furthermore, this same deletion with identical breakpoints was found in
the probands of two additional APC mutation-negative classical FAP kindreds. Phasing analysis of single nucleotide
polymorphisms (SNPs) around the deletion site in the three probands showed evidence of a shared haplotype,
suggesting a common founder deletion in the three kindreds. SNP analysis within the coding sequence of
APC, revealed that this ~11 kb deletion was accompanied by silencing of one of the APC alleles in blood-derived RNA
of affected individuals.
Conclusions: These results support the causal role of a novel promoter deletion in FAP and suggest that non-coding
deletions, identifiable using second-generation sequencing methods, may account for a significant fraction of APC
mutation-negative classical FAP families.

Background
Familial adenomatous polyposis (FAP) is an inherited,
autosomal dominant syndrome characterized by the development of colonic polyposis and cancer progression
by 40 years of age when left untreated. The classical FAP
phenotype results in the growth of hundreds to thousands of adenomas, caused in approximately 70% to 80%
of affected families by germline mutations in the tumor
suppressor gene adenomatous polyposis coli (APC) on
chromosome 5q21-22 [1,2]. An attenuated FAP phenotype results in generally fewer than 100 adenomas, and
fewer than 10% of such families have detectable APC
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mutations [1]. Mutations in the gene Mut Y homolog
(MUTYH) have been associated with an autosomal recessive form of inherited colonic polyposis and are not
observed in classical or attenuated FAP [3].
Hundreds of pathologic mutations in APC have been
described which result in FAP, most by producing a truncated protein product [4]. Such mutations occur throughout the 15 exons of APC, although mutation hot spots
occur between codons 1,000 to 1,500 of exon 15 [2,3].
Routine clinical genetic testing has therefore consisted of
Sanger sequencing of the 15 exons of APC as well as
southern blot analysis on all 15 exons to detect rearrangements or copy number variations [5]. The inability to
determine a causal mutation of FAP in ‘APC mutationnegative’ families precludes the identification of unaffected
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members and necessitates intensive colonic surveillance
of all individuals of the family [5].
Reports have begun to describe mutations surrounding
exon 1B of APC in mutation-negative families: A ~61 kb
deletion which partially overlapped promoter 1B was described in a Swedish FAP family [6]. A large deletion containing promoter 1A was found in a Mennonite family
through multiplex ligation-dependent probe amplification,
but the genomic breakpoint coordinates were not defined
[7]. A ~21 kb deletion containing promoter 1B was described in the proband and affected father of a Bulgarian
family [8]. More recently, distinct promoter deletions were
identified in APC in mutation-negative families which
were approximately 34 kb [9] and approximately 132 kb
[10] in size. These deletions are particularly relevant given
prior observations that one APC allele is silenced in many
individuals with APC mutation-negative FAP [11].
Here we investigated a multi-generational APC mutationnegative FAP kindred, using second-generation sequencing techniques that identified an ~11 kb deletion which
encompasses exon 1B and the associated promoter [12].
Furthermore, we found this deletion in two additional
FAP kindreds previously classified as APC mutationnegative by standard genetic testing. In the probands of all
three kindreds, we demonstrate the absence of a transcript from one APC allele indicating that the ~11 kb
deletion likely silences APC expression. These results
highlight the importance of second-generation sequencing
approaches to test for potentially pathologic mutations of
APC which cannot be detected by current standard genetic tests.

Methods
Study subjects

Within our FAP registry, we identified three APC mutationnegative FAP kindreds with classical phenotypes. Participants from these kindreds gave written informed consent
for participation in a study approved by the Institutional
Review Board of Washington University, St. Louis (IRB#
201105464) and which conforms to the Helsinki Declaration.
These kindreds were concentrated in three different states:
Missouri, Illinois, and Idaho, and were not known to be
related. The probands from each kindred underwent clinical genetic testing with Colaris AP® (Myriad Genetic
Laboratories, Salt Lake City, UT, USA), which sequences
15 exons of APC and exons 7 and 13 of MUTYH to detect
the mutations Y165C and G382D. Southern blot analysis
on all exons of APC is also performed to detect large rearrangements. No known pathologic mutations in APC and
MUTYH were detected by this method in the probands of
the three kindreds.
Blood from participants was collected in tubes without
additives for DNA extraction and in PAXgene Blood RNA
Tubes (PreAnalytiX; Qiagen, Valencia, CA, USA) for
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RNA preservation and extraction. DNA blood extraction
was performed using the Gentra Puregene Blood Kit
(Qiagen), and RNA blood extraction was performed using
the PAXgene Blood RNA Kit (Qiagen).
Exome sequencing and linkage analysis

Exome capture was performed with the SureSelect 38 Mb
All Exon kit (Agilent, Salta Clara, CA, USA) for members
of kindred 0124 III-5, III-3, III-4, and the SureSelect
72 Mb (V4 + UTR) kit was used for individuals 0124 IV-4,
V-6, IV-2, V-1, and IV-3. Paired-end sequencing (2 ×
101 bp) was performed on the HiSeq 2000 platform
(Illumina, San Diego, CA, USA). The sequences were
aligned against the GRCh37/hg19 human reference genome using Novoalign (Novocraft, Selangor, Malaysia), optical duplicate sequence removal was performed using
samtools [13], and variant calls were identified using samtools and GATK [14]. Local realignment and base quality
recalibration using GATK were performed prior to variant
calling, and a genotype quality GQ threshold of 20 was
used to retain single nucleotide variants (SNVs) for further analysis. All reported genomic coordinates are in
relation to the GRCh37/hg19 reference human genome.
The sequencing data is available at dbGaP with accession
number phs000904.v1.p1.
To search for candidate exon mutations which segregated with the FAP phenotype in kindred 0124, we applied
a series of filters to the identified SNVs. We required that
a candidate SNV follow an autosomal pattern of inheritance and retained only those which were heterozygous in
affected individuals and homozygous in unaffected ones.
The SNVs were annotated for function using ANNOVAR
[15], and only non-synonymous mutations were retained.
Finally, single nucleotide polymorphisms (SNPs) in
dbSNP132 [16] and identified in the 1000 Genomes
project [17] were removed. To perform linkage analysis, the unfiltered, aggregated SNVs were analyzed with
MERLIN using parametric linkage analysis with a rare
dominant disease model [18].
Coloseq™ testing and deletion validation

Subjects IV-4 of kindred 0124, IV-1 of kindred 0130, and
III-2 of kindred 0163 underwent sequencing of the APC
locus with the ColoSeq™ Polyposis Panel, which performs
second-generation sequencing of APC and MUTYH
to cover all exons, introns and flanking sequences [12].
An ~11 kb deletion encompassing exon and promoter 1B
was detected in all three individuals between coordinates
chr5:112,034,824-112,045,845. To verify the presence of
this deletion, PCR using standard conditions and primers
P1, P2, and P3 (Table 1) were used. In the presence of
template genomic DNA with the ~11 kb deletion, primers
P1 and P3 form a 298 bp PCR product, whereas primers
P1 and P2 do not result in a product because the binding
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Table 1 Primer sequences and coordinates
Primer name

Primer sequence

Left-most position of primer
(GRCh37/hg19 coordinates)

P1

5′ CTAGGCTATACCATCTAGGCTTGTG 3′

chr5:112,034,609

P2

5′ GAGGCCAGTATTACTTTGATACCC 3′

chr5:112,034,958

P3

5′ CTGACCAATATCCTCACATAGCTG 3′

chr5:112,045,903

P4

5′ GAGTTCCCTGGTGTAAATGCTCT 3′

chr5:112,032,220

P5

5′ CCCTAACAACCAGTCTGAGTAGC 3′

chr5:112,032,727

P6

5′ AGTAAACCTGGAAAGAGCACCAC 3′

chr5:112,032,926

P7

5′ CTTCTAGTACTTAAAGGGACAGCACC 3′

chr5:112,033,107

P8

5′ ATCCTCCATATCTGTGGGTTCTG 3′

chr5:112,034,220

P9

5′ GCTCTGCTTAACGACAGGAATAC 3′

chr5:112,034,692

P10

5′ GTAGAGGCCAGATACACTAATGTCC 3′

chr5:112,049,943

P11

5′ CTACTATGCCAGACAGTATTCCAGAC 3′

chr5:112,050,557

P12

5′ CCAGAGATCAGTAGTCTTTCCAGAG 3′

chr5:112,051,725

P13

5′ CAGAGACCTGCACTCAATAAATGG 3′

chr5:112,052,217

P14

5′ ACAGTGTCTGGCTCTCTGAGATACT 3′

chr5:112,029,655

P15

5′ CATCTATGTAGGCTAGAGAGGGAGA 3′

chr5:112,046,239

P16

5′ AGTTAGCTGCTGGAGAAGGAGTTAG 3′

chr5:112,176,294

P17

5′ GCTGGTAACTTTAGCCTCTGATTC 3′

chr5:112,176,956

P18

5′ GAATCAGAGGCTAAAGTTACCAGC 3′

chr5:112,176,956

P19

5′ GTCACTGAGAGAACTCAGAGAGGAA 3′

chr5:112,177,189

site for primer P2 is absent. With a normal genomic DNA
template, primers P1 and P2 form a 373 bp product,
whereas primers P1 and P3 do not form a product because the distance of their binding sites exceeds 11 kb.
The PCR amplicons were sequenced with Sanger chemistry using the ABI BigDye Terminator Mix (version 3,
Applied Biosystems, Foster City, CA, USA).
SNP genotyping and haplotype phasing

To query SNPs flanking the promoter deletion, the following primer pairs were used (Table 1): primers P4/P5
for rs76768628, rs60905866, and rs10463643; primers
P6/P7 for rs10051624; primers P8/P9 for rs2900066,
rs6594643, and rs6594644; primers P10/P11 for rs4705559
and rs7704618; and primers P12/P13 for rs1661035 and
rs76028897. To amplify DNA specifically from the
chromosomal strand harboring the ~11 kb deletion, two
primer pairs were used: P8/P13 and P14/P15 (Table 1).
On chromosomes with the ~11 kb deletion, these primer
pairs resulted in amplicons of 5,541 bp and 6,956 bp in
size, respectively. Because these amplicons represent
DNA amplified only from the chromosomal strand with
the ~11 kb deletion, all of the SNP genotypes determined
from these amplicons were used as templates for Sanger
sequencing (and haplotype phasing) using primers P4, P6,
P8, P10, and P12 (Table 1).

Allelic expression assessment

dbSNP was searched for SNPs residing in the coding region of APC, and rs459552 and rs465899 were found to be
heterozygous in the exome sequence data of one or more
individuals of kindred 0124. After extraction of RNA from
blood collected in PAXgene Blood RNA Tubes, reverse
transcription was performed using SuperScript III Reverse
Transcriptase (Invitrogen, Grand Island, NY, USA). The
following primers were used to perform PCR and subsequent sequencing for SNP assays (Table 1): primers P16/
P17 for rs459552 (producing amplicon chr5:112,176,294112,176,979) and primers P18/P19 for rs465899 (producing amplicon chr5:112,176,956-112,177,213).

Results
Exome sequencing of a classical FAP family reveals a LOD
peak at the APC locus

Kindred 0124 is a multi-generational family with a classical FAP phenotype (Figure 1A), including the presence
of multiple extra-colonic malignancies but with no mutations in APC using standard genetic testing. To investigate
the causal mutation accounting for FAP, we performed exome sequencing on eight individuals spanning three generations of the 0124 kindred. Analysis of the exome data
revealed one non-synonymous heterozygous mutation
which segregated in the affected family members and did
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Figure 1 Exome sequencing in APC mutation-negative kindred 0124 revealed positive LOD scores at the APC locus. (A) Affected
members of kindred 0124 have classical FAP phenotypes with highly-penetrant, autosomal dominant inheritance across the family. Extra-colonic
malignancies were unusually common in this kindred, including duodenal adenocarcinoma (in two members), pancreas adenocarcinoma, gastric
adenocarcinoma, breast cancer, leukemia, ovarian adenocarcinoma, endometrioid carcinoma, and neuroendocrine carcinoma. The proband (III-5,
arrow) underwent standard genetic testing and no known FAP-causing mutation was identified. Asterisks indicate the eight individuals who
underwent exome sequencing. Analysis did not reveal a credible causal mutation within the exonic sequences. Parametric linkage analysis using
a rare autosomal dominant model with SNPs identified from the exome sequencing data was then performed. (B) LOD scores are plotted across
somatic chromosomes, with positive LOD score regions marked in red and negative scores marked in blue. The maximum LOD of 2.408 occurred
at 5q22, which contains the APC locus.

not appear in dbSNP132 or an in-house exome sequence
database. This was a c.G512A (p.R171Q) mutation in the
gene Proline Rich Protein BstNI Subfamily 2 (PRB2) at coordinate chr12:11,546,500. PRB2 is a member of a class of
genes located on chromosome 12p13.2 which code for
abundant proteins in salivary excretion [19]. Of note, this
SNP has appeared in dbSNP as of version 135 and has a
minor allele frequency of 0.009 in dbSNP 137. The significance of this non-synonymous mutation remains unclear
in relation to the FAP phenotype.
Considering the possibility of a non-coding mutation accounting for the FAP phenotype, we turned to linkage
analysis using SNPs derived from exome sequencing data.
Using parametric linkage analysis with a dominant disease
model [18], we found several loci with positive logarithm
of the odds (LOD) scores, although none had a LOD score
over 3 (Figure 1B). We did not find a positive LOD score
around the PRB2 locus, further indicating a lack of support for the role of PRB2 in the FAP phenotype. However,
we found two loci with a maximum LOD score of 2.408 one at 5q22.2 (111.5 to 112.9 Mb) and another at 7p14.1

(37.2 to 43.3 Mb). 5q22.2 notably contains the APC gene
and suggested the possibility of a non-coding APC mutation being causal in this FAP kindred. Because of the
known relationships between APC and FAP, we chose to
focus the remainder of this study at the APC locus.
Second-generation sequencing of the APC locus reveals
an 11 kb promoter deletion

To search for a non-coding mutation at the APC locus
of the affected individual IV-4 of kindred 0124, we used
the ColoSeq™ assay to capture and sequence exonic, intronic, and promoter regions of the APC gene [12]. This
assay identified an ~11 kb heterozygous deletion 44 kb
upstream of the first exon of APC between coordinates
chr5:112,034,824-112,045,845 (Figure 2). This deletion
contains exon and promoter 1B (Genbank D13981.1)
and represents the smallest promoter deletion currently
described in an FAP family.
We verified the presence of the deletion using primers
designed to create a PCR product of 373 bp when a genomic template with normal APC promoter is present

Figure 2 Second-generation sequencing across the APC locus revealed an ~11 kb heterozygous deletion. Affected individual IV-4 of
kindred 0124 (red bar) was subjected to second-generation sequencing across the APC locus including the promoter, exons and introns. A
heterozygous deletion approximately 44 kb upstream of APC exon 1A was found between coordinates chr5:112,034,824 and chr5:112,045,845
(GRCh37/hg19) which encompasses exon and promoter 1B (Genbank D13981.1). Other studies (Snow et al., Rohlin et al., and Kadiyska et al.) have
reported larger promoter deletions in this region [6,8-10] (blue bars).
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Figure 3 The heterozygous ~11 kb APC deletion is present in all affected members of the 0124 kindred. (A) Primers were designed to
bind upstream of the ~11 kb deletion (primer 1), within the deletion (primer 2), and downstream of the deletion (primer 3). In the presence of a
normal allele, primers 1 and 2 result in a 373 bp PCR product. Primers 1 and 3 do not form a product in the absence of the ~11 kb deletion but
form a 298 bp PCR product when the deletion is present. (B) In the five affected members of kindred 0124 (III-5, IV-4, V-6, III-3, and IV-2), PCR
using these primers resulted in two fragments of the expected sizes. In the three unaffected members (III-4, V-1, and IV-3), PCR produced only
one fragment. (C) Sanger sequencing of the PCR product from affected member III-5 using primer 3 confirmed the presence of the ~11 kb
deletion. The sequencing trace transitions from coordinate chr5:112,034,825 to chr5:112,045,846 (GRCh37/hg19), a span of 11,020 bp. (D) Sequencing
the same PCR product using primer 2 showed the presence of a normal allele and the absence of the gap with a transition from coordinate
chr5:112,034,825 to chr5:112,034,826.

(primers 1 and 2, Figure 3A). A second primer pair creates a 298 bp PCR product only when a genomic template with the ~11 kb deletion is present (primers 1 and
3, Figure 3A). We used these primers to assess the eight
members of kindred 0124 (Figure 3B). PCR in all five affected individuals generated both 298 bp and 373 bp products, indicating heterozygosity for the promoter deletion
allele in APC. In the three unaffected individuals, only the
373 bp fragment was generated indicating the absence of
the promoter deletion.
Further verifying the presence of the ~11 kb promoter
deletion, we performed Sanger sequencing of the PCR
products from the proband of kindred 0124. Using primer 3 for Sanger sequencing, we confirmed an 11,020 bp
gap in the mapped coordinates from the sequencing
trace (Figure 3C). Sanger sequencing using primer 3
also confirmed the presence of a normal allele in the
proband (Figure 3D).
11 kb promoter deletion is found in two additional FAP
kindreds

Two additional kindreds in our FAP registry were found
to be APC mutation-negative by standard genetic testing.
These kindreds, 0130 and 0163 (Figure 4A and C), reside
in different states in America and have no known familial
relationship to each other or to the index kindred 0124.
To assess the presence of promoter deletions in these two

additional FAP kindreds, we used the ColoSeq™ assay to
sequence the APC locus in each proband and surprisingly
found the same ~11 kb deletion. Further investigation
using Sanger sequencing confirmed the identical deletion
coordinates in both probands (Figure 4B and D). To exclude possible sample error, we verified those findings in a
second blood sample from the probands of all three kindreds 1 year after obtaining the first samples, reinforcing
our conclusions that affected members from these independent kindreds indeed harbor the identical mutation.
Genetic relationship between kindreds revealed by
haplotype phasing

As alluded to above, these three kindreds reside in geographically distinct regions and no known relatedness was
discerned by questionnaire. Nevertheless, we examined
genetic evidence of a relationship between these kindreds
by determining the genetic haplotype associated with
the ~11 kb deletion in each of the three probands. We
first queried 11 SNPs flanking the deletion coordinates
(Table 2), seven of which ranged from 229 to 2,408 bp 5′
of the deletion, and four of which ranged from 4,276 to
6,151 bp 3′ of the deletion. SNPs rs10463643, rs10051624,
rs2900066, rs6594643, rs6594644, rs4705559, rs7704618,
and rs1661035 were heterozygous in the probands of the
0124 and 0163 kindreds. These findings suggested that
these SNPs could distinguish the haplotype associated
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Figure 4 The ~11 kb APC deletion is found in two other APC mutation-negative kindreds. (A, C) Affected members of kindreds 0130 and
0163 have the classical FAP phenotype, and standard genetic testing of probands IV-1 in kindred 0130 and III-2 in kindred 0163 (arrows) did not
identify known pathologic mutations of APC. Second-generation sequencing across the APC locus in the probands suggested that both had the
same heterozygous ~11 kb APC deletion found in the index kindred 0124. Sanger sequencing using primer 3 confirmed the presence of the same
deletion coordinates from chr5:112,034,825 to chr5:112,045,846 in the probands 0130 (IV-1) (B) and 0163 (III-2) (D). Sequencing using primer 2 in
both probands showed the presence of a normal allele as well, with contiguous coordinates from chr5:112,034,825 to chr5:112,034,826.

Table 2 Haplotype phasing by SNP genotyping
Reference

Distance (bp)a

0124

rs76768628

A

2408

A/A

A

A/A

A

A/A

A

rs60905866

G

2250

G/G

G

G/G

G

G/G

G

rs10463643

C

2150

C/T

T

T/T

T

C/T

T

rs10051624

G

1781

G/C

G

G/G

G

G/C

G

rs2900066

A

473

A/T

T

T/T

T

A/T

T

rs6594643

C

275

C/A

C

C/C

C

C/A

C

rs6594644

T

229

T/G

T

T/T

T

T/G

T

SNP

0124 phasedb

0130

0130 phasedb

0163

0163 phasedb

SNPs 5′ to deletion

SNPs 3′ to deletion
rs4705559

A

4276

A/G

A

A/A

A

A/G

A

rs7704618

T

4619

T/G

T

T/T

T

T/G

T

rs1661035

G

5982

G/C

C

C/C

C

G/C

C

rs76028897

A

6151

A/A

A

A/A

A

A/A

A

a

Distance from the adjacent breakpoint coordinate of deletion chr5:112,034,826-112,045,845.
b
SNP typing of phased PCR amplicons.
Positions which differ from the reference base are denoted in bold.
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with the ~11 kb deletion from the haplotype from the
chromosomal strand without the deletion. Accordingly we
phased the SNP genotypes by using a PCR strategy to
selectively amplify the DNA from the chromosomal
strand containing the ~11 kb deletion (Figure 5). Flanking
primers were designed such that amplicons of 5.5 kb and
6.9 kb would reflect the deletion, whereas amplification
from the wild type chromosomal strand would yield an
amplicon 11 kb larger. Accordingly, we then isolated the
5.5 and 6.9 kb amplicons for Sanger sequencing as a result
of which we were able to phase the SNP genotypes associated with the deletion. The sequencing results showed
that the haplotype associated with the ~11 kb deletion
was identical across the queried SNPs in each of the three
probands (Table 2), providing evidence to suggest that
these three kindreds share a common ancestor.
APC promoter deletion results in allelic silencing in blood

APC is transcribed in a wide variety of tissues, including peripheral blood cells [6]. To assess the effect of
the ~11 kb deletion on allelic transcription in these
kindreds, we identified exonic SNPs in APC which were
heterozygous in the germline of affected and unaffected
individuals of these FAP kindreds. Silencing of an APC allele in individuals heterozygous for these SNPs would result in the detection of only one base at the corresponding
complementary DNA (cDNA) site from expression of a
single APC allele. Sanger sequencing of genomic DNA
(gDNA) from proband III-5 of kindred 0124 showed heterozygousity at SNPs rs459552 and rs465899, but sequencing of cDNA derived from blood shows the presence of
only one allele for both corresponding positions. This is in
contrast to the unaffected individual III-4 of kindred 0124
whose gDNA is heterozygous for SNP rs465899, and in
whom cDNA sequencing shows evidence of mRNA expression from two alleles (Table 3 and Figure 6). The silencing of one APC allele was also observed in affecteds
from the other two kindreds with loss of cDNA heterozygosity at SNP rs459552 in proband IV-1 of kindred 0130,
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and SNPs rs459552 and rs465899 in proband III-2 of kindred 0163 (Table 3 and Figure 6).

Discussion
Here we report the presence of a novel ~11 kb heterozygous deletion in the APC promoter of three independent
APC mutation-negative classical FAP kindreds. Our
findings add to the growing body of literature suggesting
that non-coding APC deletions may contribute to an important fraction of APC mutation-negative classical FAP.
The current literature is based in reports of a founder
mutation in a Mennonite kindred, a kindred in the Swiss
Polyposis Registry, and a single Bulgarian kindred [6-8].
However, this is the first report to our knowledge that
the identical mutation exists in three classical FAP kindreds. In addition, there are informative features of the
approach we used to identify this mutation that bear further discussion.
Our evaluation began with the exome sequencing of
one multigenerational family with classical FAP to address
the possibility that the causal mutation was a coding mutation in a novel gene. We identified a non-synonymous
heterozygous mutation that segregated with the polyposis
phenotype across the kindred. However, this mutation in
PRB2 remains of unclear significance since database
searches revealed no plausible connection to FAP or
gastrointestinal polyposis in general. Our experience parallels that of others showing some of the potential pitfalls
in using exome sequencing to search for causal mutations
in Mendelian diseases. For example, in the search for the
causal mutation for Kabuki syndrome, Ng et al. performed
exome sequencing on 10 unrelated affected individuals
and found one rare, non-synonymous mutation (in
MUC16) across all 10 individuals [20]. However, this particular mutation was felt to be a false positive result, and
further investigations identified a more likely mutation
candidate (MLL2).
Although exome sequencing has been used successfully
to identify over 100 Mendelian disease genes [21,22], the

Figure 5 Schematic of primer design for haplotype phasing of SNP genotypes in relation to the ~11 kb APC deletion. The primer pairs
P14/P15 and P8/P13 flanked the ~11 kb deletion and relevant SNPs. Only amplification of the APC allele with the ~11 kb deletion would result in
an amplicon A size of 5.5 kb and an amplicon B size of 6.9 kb. Amplification of the allele without the ~11 kb deletion would not be efficient, as
the resultant amplicons would be greater than 16 kb. Amplicons A and B were used as templates for Sanger sequencing reactions to reveal
polymorphic variations in the diagrammed SNPs flanking the ~11 kb deletion.
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Table 3 Sanger sequencing evaluation of APC SNPs in
gDNA and RNA of affected and unaffected individuals
Subject
0124 (III-5) 0124 (III-4)
SNP

Affected

rs459552 gDNA A/T
cDNA

A/A

rs465899 gDNA A/G
cDNA

A/A

0130 (IV-1) 0163 (III-2)

Unaffected Affected

Affected

-/-

A/T

A/T

-/-

A/A

A/A

A/G

-/-

A/G

A/G

-/-

A/A

Sequences which are heterozygous are denoted in bold.
cDNA, complementary DNA; gDNA, genomic DNA.

number of unsuccessful applications of this technique is
unknown. Several reasons may result in the inability to
identify a mutation using exome sequencing: False negatives can result from technical issues such as poor capture
and subsequent low sequence coverage of exons, or from
analytical errors such as from indiscriminant candidate filtering using SNPs from public databases. Although the
Agilent SureSelect Human All Exon V4 + UTR probe set
captured DNA from exon 1B in our study, data from targeted capture and exome sequencing are generally not
amenable to the discovery of copy number variations because of technical biases. Sequence coverage of exon 1B
did not differ between affected and non-affected members
of kindred 0124 (data not shown) and therefore did not
reflect the ~11 kb deletion. Although the exome sequencing strategy did not yield directly a causal variant, we
were able to perform linkage analysis using SNPs derived
from the exome sequences. The linkage data did not yield
a LOD score significant at the whole genome level, but of
the positive signals identified, the one of obvious interest
was at the APC locus.
We further investigated the APC locus, using a secondgeneration sequencing assay across the non-coding regions to reveal an ~11 kb deletion. Unlike array-based or
multiplex ligation-dependent probe amplification (MLPA)

techniques used to search for regions of copy number
variation, the second-generation sequencing assay was
able to identify the exact breakpoint coordinates. These
were further confirmed by an orthogonal sequencing modality with Sanger chemistry. Presumably, another benefit
of the second-generation sequencing is the ability of the
technique to detect diminutive copy number variants
down to insertion/deletions of a few bases in length,
whereas array or MLPA techniques are able to detect only
large variants greater than kilobases in length. Unexpectedly, we found the same deletion breakpoints in all three
independent APC mutation-negative kindreds in our FAP
registry. The phased typing of SNPs flanking the ~11 kb
deletion further showed that the three kindreds shared the
same haplotype associated with the deletion, which suggests that the deletion in these kindreds arose from a
common ancestor.
This ~11 kb deletion encompasses exon and promoter
1B, and using SNP analysis on APC transcripts, we found
that this deletion silenced one APC allele in affected individuals. Rolin et al. described a ~61 kb heterozygous deletion which resulted in a reduction in expression, but not
silencing, of an APC allele [6]. This ~61 kb deletion
removes a portion of the exon 1B 5′ untranslated region
but does affect an open reading frame within it (RefSeq
NM_001127511.2). The ~11 kb deletion described in this
study, by contrast, deletes exon1B and its upstream sequences in its entirety. It may be that the deletion of
the exon 1B 5′ untranslated region and/or its open reading frame results in its targeted degradation. Interestingly however, a ~21 kb deletion which encompasses
the ~11 kb deletion described in this study was reported
to reduce, but not to silence, allelic expression of APC [8].
The interaction of 1A and 1B promoters in different tissue
types and other epigenetic regulatory mechanisms need
further investigation. For example, although our results
show that the ~11 kb deletion results in diminished transcription of APC in blood, differential promoter use may

Figure 6 The ~11 kb deletion silences one APC allele in the blood of affected individuals. Germline heterozygous SNPs were evaluated in
the RNA isolated from peripheral blood, with sample traces shown here. dbSNP rs465899 was found to be heterozygous in the proband 0124
(III-5) gDNA but not in the cDNA, whereas this SNP was heterozygous in both gDNA and cDNA in the unaffected subject 0124 (III-4). A loss of
cDNA heterozygosity was also observed in proband 0130 (IV-1) with SNP rs459552, and in proband 0163 (III-2) with SNP rs465899.
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still result in APC transcript production using promoter
1A in other tissues.
The allelic silencing of APC in mutation-negative kindreds is consistent with observations made over a decade
ago. Using a method of isolating individual chromosomes
from affected individuals in hybrid rodent cells to perform
monoallelic mutation analysis, one APC allele was found
to be silenced in seven of nine FAP subjects [11]. The
mechanism of allelic silencing could not be determined at
that time, however.

Conclusions
We provide evidence that an ~11 kb deletion encompassing exon and promoter 1B of APC which segregates
with the FAP phenotype in three affected kindreds results in allelic silencing. Second-generation sequencing
techniques is ideal for the detection of such deletions, as
they can vary greatly by size and position (Figure 2). Furthermore, the availability of such assays in the clinical
setting such as with ColoSeq™ has the potential to readily impact the clinical management of FAP kindreds.
Abbreviations
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